KO Validated
HBEGF
Reactivity: Human
WB
Host: Rabbit
Monoclonal
unconjugated
Application Notes
The antibody can react with both soluble and cell-surface attached forms of HG-EGF. 1) Westernblotting: 0. 2~1 g/mL 2) Immunoprecipitation: 1 g/mL 3) Indirect immuno-fluorescence staining: 5~11 g/mL
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PBS with 50 % Glycerol
Preservative
Azide free
Storage
-20 °C
Storage Comment
Upon arrival centrifuge briefly, aliquote and store at -20 C.
Miyamoto, Hirata, Yamazaki, Kageyama, Hasuwa, Mizushima, Tanaka, Yagi, Sonoda, Kai, Kanoh, Nakano, Mekada: "Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy." in: Cancer research, Vol. 64, Issue 16, pp. 5720-7, (2004) (PubMed).
Prenzel, Zwick, Daub, Leserer, Abraham, Wallasch, Ullrich: "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF." in: Nature, Vol. 402, Issue 6764, pp. 884-8, (2000) (PubMed).
Iwamoto, Higashiyama, Mitamura, Taniguchi, Klagsbrun, Mekada et al.: "Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin ..." in: The EMBO journal, Vol. 13, Issue 10, pp. 2322-30, (1994) (PubMed).
Higashiyama, Abraham, Miller, Fiddes, Klagsbrun: "A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF." in: Science (New York, N.Y.), Vol. 251, Issue 4996, pp. 936-9, (1991) (PubMed).
Background: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is synthesized as a membrane-anchored precursor that is proteolytically cleaved to release the soluble mature growth factor, HB-EGF. The former functions as juxtacrine and the latter as paracrine growth factor. Soluble HB-EGF shows several forms in Western blotting with apparent molecular weights 19~27 kDa due to heterogeneous O-glycosylation and N-terminal truncation. HB-EGF activates EGFR and ErbB4 and promotes the development in many tissues. In human ProHB-EGF is the cellular receptor for diphtheria toxin. Non-toxic mutant of diphtheria toxin, CRM197, inhibits HB-EGF function. As HB-EGF level is elevated in most ovarian cancer, CRM197 is being tested as an anticancer drug. The hybridoma clone 4G10 was established and characterized in the laboratoryof Prof. E.Mekadaof OsakaUniversity, who is a leadingscientist inthis field.